Transcriptome Analysis Reveals the Immune Infiltration Profiles in Cervical Cancer and Identifies KRT23 as an

Xia Li1, Yan Cheng1, Yanmei Cheng2

  • 1Gynecological Oncology Radiotherapy Ward, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Oncology
|July 11, 2022
PubMed

Insights

This study reveals distinct immune cell infiltration patterns in cervical cancer (CC), identifying Keratin 23 (KRT23) as a potential immunotherapy target. A predictive model for CC patient survival was also developed.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Cervical cancer (CC) poses a significant global health challenge with limited conventional treatment efficacy.
  • Immunotherapy effectiveness in solid tumors is influenced by the tumor microenvironment (TME).
  • Understanding CC's TME is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To characterize immune cell infiltration in cervical cancer.
  • To investigate the relationship between immune cell infiltration and genomic alterations.
  • To identify potential therapeutic targets and prognostic biomarkers for CC.

Main Methods:

  • Utilized ssGSEA and xCell for immune profiling of CC tissues.
  • Performed consensus clustering to categorize CC samples based on immune cell infiltration.
  • Conducted enrichment analyses of differentially expressed genes (DEGs) and in vitro experiments.

Main Results:

  • CC tissues showed higher adaptive and lower innate immune cell infiltration compared to normal tissues.
  • Four distinct immune clusters were identified, with 'hot' tumors demonstrating greater immune infiltration and improved survival.
  • Keratin 23 (KRT23) was upregulated in 'cold' tumors and its knockdown promoted CD8+ T cell recruitment.

Conclusions:

  • CC exhibits complex immune infiltration patterns, differentiating 'hot' and 'cold' tumors.
  • KRT23 presents a promising target for CC immunotherapy by enhancing immune cell infiltration.
  • A DEG-based model shows high predictive power for CC patient prognosis, potentially guiding clinical immunotherapy decisions.